胰岛B细胞功能恢复的新途径

A new approach to recovery of islet B-cell function

随着人们生活水平提高,糖尿病患病率逐渐增长,临床上必须开发新方法以减少糖尿病前期与2型糖尿病发生发展。本文总结了过去十年口服降糖药物(磺酰脲类、胰高血糖素样肽、二肽基肽酶4抑制剂、钠-葡萄糖协同转运蛋白-2抑制剂)在改善B细胞胰岛素的分泌或靶组织对胰岛素敏感性方面取得的成果;描述了通过多途径内源因子、遗传学和表观遗传学途径,在改善B细胞功能障碍和外周胰岛素敏感性方面取得的突破,这些新方法从多角度理解和解决了2型糖尿病的发病机制。

With the improvement of people’s living standards and the prevalence of diabetes. Clinically, new methods must be developed to reduce the development of pre-diabetes and type 2 diabetes. This article summarized the past decade of oral hypoglycemic drugs (sulfonylureas, glucagon-like peptides, dipeptidyl peptidase 4 inhibitors, sodiumglucose cotransporter-2 inhibitors) in improving B cell insulin secretion or the achievement of insulin sensitivity in target tissues;described breakthroughs in improving B cell dysfunction and peripheral insulin sensitivity through multiple pathways of endogenous factors, genetics, and epigenetic pathways, these new approaches multi-angle understanding and solution to the pathogenesis of type 2 diabetes.